Search results for: Market Access
Filter search results
OHE Lecturing for Professional Training at ICPS
5 February 2019
…including decentralisation, contracting, and market mechanisms). Even though some general lessons have been learnt from the implementation of these policies in different countries, as shown by a recent OECD study,…
OHE at the 2019 Health Technology Assessment International (HTAi) Annual Meeting
7 June 2019
…and the incremental cost-effectiveness ratio, per year and aggregated (1994-2017). Results suggest that market access decisions at launch should consider the value added by innovative medicines over their entire life-cycle….
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…accrue from lower prices when the product goes off-patent, or whilst still on-patent, when new competitors of the same class enter the market. The present work aims to assess…
Is There a Productivity Crisis in Pharmaceutical R&D?
6 January 2012
…changes in both the regulatory and marketing climates. In addition to describing overall trends, Prof Riccaboni also compares the R&D performance of companies based in the US and Europe, and…
Innovation in Industry: a Factor for Growth
1 July 1969
…produce and sell new products which are more advanced, more efficient, or of better design than those of our competitors in world markets. Secondly, it is clear that the UK…
Pharmaceutical Innovation: Recent Trends, Future Prospects
1 October 1983
…medicines becoming available for patient use. Indeed, the opposite has been the case: new market entries – including reformulations, new combinations, additional modes of presentation and new chemical entities —…
Pharmaceuticals in Developing Countries
1 July 1983
…data on the activities of the industry in the Poor World, together with improvements in its standards of marketing practice, will soon reveal the nature of its benefits there too….
Personalised Medicine: Is it an Oil-Rush or Oil-Spill?
3 February 2020, 12:00am
…accepted this will change the whole process of regulating new medicines. The seminar will also discuss how personalized medicine also threatens to disrupt the insurance market, making it difficult to…
News Release: Report on Patient Choice in the UK
4 June 2010
…a major reason why patients choose to access care from an alternative provider. Few patients are making use of performance data to inform their choices – just 4 per cent…